AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPsychiatry and PsychologyPhenomena and ProcessesInformation ScienceHealth Care
Partial Thromboplastin TimeProthrombin TimeBlood Coagulation TestsThrombin TimeBlood CoagulationBlood Coagulation DisordersAnticoagulantsHeparinHirudin TherapyLupus Coagulation InhibitorThrombelastographyHeparin AntagonistsAntithrombinsPipecolic AcidsHemorrhageHirudinsHemostasisHypoprothrombinemiasWhole Blood Coagulation TimeAdministration, OralBlood Coagulation FactorsFactor VIIIRadiation DosageLethal Dose 50Factor XaBlood Coagulation Disorders, InheritedHemorrhagic DisordersHemophilia ABleeding TimeFactor IXThromboembolismFibrinogenCoagulantsThrombinInfusions, IntravenousTime FactorsProthrombinThrombosisDrug MonitoringPlatelet CountInjections, IntravenousProtein CDrug Administration ScheduleAntithrombin IIIActivated Protein C ResistanceHemostatic DisordersRadiometryInternational Normalized RatioHemostaticsTreatment OutcomeHemophilia Bbeta-AlanineVitamin K DeficiencyDisseminated Intravascular CoagulationHeparin, Low-Molecular-WeightChromogenic CompoundsDogsDose-Response Relationship, RadiationFibrinolytic AgentsDose FractionationThrombocytopeniaPlasmaRadiotherapy DosageDouble-Blind MethodIndicators and ReagentsWarfarinEnoxaparinRecombinant ProteinsVitamin KFibrinolysisBlood Specimen CollectionThromboplastinPopulationFibrin Fibrinogen Degradation ProductsProspective StudiesArea Under CurveAntiphospholipid SyndromeThrombophiliaDog DiseasesBenzimidazolesRadiotherapy Planning, Computer-AssistedHalf-LifeFactor VDose-Response Relationship, DrugReference ValuesRabbitsBody BurdenThermoluminescent DosimetryRats, Sprague-DawleyDrug InteractionsRetrospective StudiesRelative Biological EffectivenessVenous ThrombosisPlatelet AggregationImmunologic FactorsDrug Therapy, CombinationBiological AvailabilityLaboratoriesAntineoplastic AgentsNeoplasms
HeparinActivated partTherapeuticProthrombin timeLMWHAnticoagulantPlateletAnticoagulationWarfarinPartial throFibrinogenThrombosisAcuteAdministerRepeated dose toxicityDabigatranParametersEnoxaparinInfusionBased on the patient'sAdjustFindingsLast doseSingle-doseSyringeHighGuidelineDaysVialStudyTestMiceHoursPatientsDailySafe
Heparin10
  • Because it can be given subcutaneously and does not require APTT monitoring, LMWH permits outpatient treatment of conditions such as deep vein thrombosis or pulmonary embolism that previously mandated inpatient hospitalization for unfractionated heparin administration. (wikipedia.org)
  • They were anticoagulated with weight-based intravenous heparin to maintain an activated partial thromboplastin time (aPTT) of 50-80 seconds. (hindawi.com)
  • Following device insertion, the patients were most frequently supported with 1 : 1 counter pulsation, and, per our group's standardized strategy, anticoagulated with a 50 U/kg weight-based bolus of heparin and subsequently started on a weight-based drip to maintain an activated partial thromboplastin time (aPTT) of 50-80 seconds for the duration of device of implantation. (hindawi.com)
  • It is sensible to use warfarin in low doses and gradually increase once every few weeks while concomitant administration with heparin is continued. (gponline.com)
  • The dose-response relationship is not linear and the anticoagulant effect increases disproportionately as doses are increased, so heparin therapy requires intensive monitoring. (gponline.com)
  • The activated partial thromboplastin time (APTT) has been used to monitor therapeutic doses of unfractionated heparin. (gponline.com)
  • patients receiving therapeutic anticoagulation (such as low-molecular-weight heparin or warfarin) should be on a stable dose. (bcan.org)
  • A chemically synthesized heparin pentasaccharide (Institut Choay, Paris, France) has been shown to exhibit an antithrombotic action in a rabbit stasis induced thrombosis model, in an IV dose range of 25 to 200 micrograms/kg (0.5 to 3.5 micrograms/ml plasma circulating concentrations). (nih.gov)
  • This patient's clinical presentation is consistent with heparin resistance, which occurs when the activated partial thromboplastin time (aPTT) does not increase into the therapeutic range despite increasing doses of heparin or when unusually high doses of heparin are required to achieve a therapeutic aPTT. (acponline.org)
  • For patients receiving intravenous heparin, give the first dose of dabigatran about 2 hours after discontinuing intravenous heparin. (jwatch.org)
Activated part5
Therapeutic2
  • patients receiving therapeutic anticoagulation should be on a stable dose for at least 4 weeks prior to the first dose of study intervention) Note: Laboratory tests with exclusionary results judged by the investigator as not compatible with the patient's clinical status may be repeated once for eligibility purposes. (uclahealth.org)
  • However, it has a narrow therapeutic window and a highly unpredictable dose response. (surgicalneurologyint.com)
Prothrombin time1
LMWH2
  • The APTT is insensitive to LMWH and cannot be used for dosage monitoring. (gponline.com)
  • If LMWH is used, obtain an anti-activated factor X (anti-Xa) level and adjust the dose to achieve a level of 0.5-1 U/mL. (medscape.com)
Anticoagulant2
  • Global anticoagulant activities were not found by PT and APTT methods. (nih.gov)
  • They have a more predictable anticoagulant effect which allows fixed dosing without the need for laboratory monitoring [ Table 1 ]. (surgicalneurologyint.com)
Platelet1
Anticoagulation3
  • For patients requiring more rapid initiation of anticoagulation, regimens starting with 5mg doses, or a single 10mg dose followed by 5mg doses, are often used. (gponline.com)
  • For patients receiving parenteral subcutaneous anticoagulation, give the first dose of dabigatran just before the next scheduled injection of parenteral anticoagulation. (jwatch.org)
  • The results suggest that sufficient anticoagulation efficacy may not be maintained when the dabigatran dose is excessively reduced to 75 mg twice daily. (biomedcentral.com)
Warfarin5
  • For patients switching from warfarin to dabigatran, give the first dose of dabigatran after the INR has declined to less than 2.0. (jwatch.org)
  • In practice, this usually means withholding one or two doses of warfarin. (jwatch.org)
  • Adjust the warfarin dose to maintain a target INR of 2.5 (INR range, 2 to 3) for all treatment durations. (druglib.com)
  • For high-risk patients with MI (e.g., those with a large anterior MI, those with significant heart failure, those with intracardiac thrombus visible on transthoracic echocardiography, those with AF, and those with a history of a thromboembolic event), therapy with combined moderate-intensity (INR, 2 to 3) warfarin plus low-dose aspirin (≤ 100 mg/day) for at least 3 months after the MI is recommended. (druglib.com)
  • Children with thromboembolism and persistent risk factors may be treated for 3 months and then switched to low-dose warfarin until the risk factor is no longer present. (medscape.com)
Partial thro1
  • Subsequently, tile spasm was admitted to our hospital partial thromboplastin time (aPTT) laboratory findings returned to normal in November 2012, to regulate her 54 s, D-dimer 2.7 mg/L (reference and control blood culture was negative. (who.int)
Fibrinogen1
Thrombosis2
  • When thrombosis was suspected or confirmed, the dose was increased to 1 mg/kg every 12 hours and adjusted with anti-Xa factor activity. (cdc.gov)
  • If the surgery is completely elective, and if the patient is at low risk of stroke or other thrombosis, wait 3 half lives, and omit 3 doses of dabigatran. (jwatch.org)
Acute2
  • High treatment doses are contraindicated in acute bleedings such as cerebral or gastrointestinal haemorrhage. (wikipedia.org)
  • The adaptive response is effective for chromosome induction, acute death, and tumorigenesis induced by high doses of radiation. (go.jp)
Administer1
Repeated dose toxicity1
  • Therefore, the aim of this study was to obtain safety data for new TiO 2 powder, GST produced through sludge recycling of the sewage treatment plant through repeated-dose toxicity in Sprague-Dawley (SD) rats in according to the OECD test guideline (TG 408). (eaht.org)
Dabigatran8
  • If a patient suffers a recurrent thromboembolic event, take a careful history to determine whether one or more doses of dabigatran were omitted. (jwatch.org)
  • If a patient who is taking dabigatran has to be taken to a surgical procedure, how long do we have to wait after the last dose of the drug? (jwatch.org)
  • If the surgery is urgent, the maximal risk of bleeding should diminish as long as one dose of dabigatran is omitted. (jwatch.org)
  • however, excessive dose reduction below that indicated on the package insert may decrease the effectiveness of dabigatran. (biomedcentral.com)
  • In this study, we investigated the incidence of thromboembolic events and hemorrhagic complications in patients receiving different doses of dabigatran, including patients receiving the very low-dose of 75 mg twice daily. (biomedcentral.com)
  • A total of 701 subjects received dabigatran during the study period: 187 patients (26.7%) received 150 mg twice daily (normal dose), 488 patients (69.6%) received 110 mg twice daily (low-dose), and 26 patients (3.7%) received 75 mg twice daily (very low-dose). (biomedcentral.com)
  • However, very few patients are prescribed dabigatran at a very low dose of 75 mg twice daily, probably due to safety concerns. (biomedcentral.com)
  • A meta-analysis of these trials concluded that dabigatran at a fixed dose was noninferior to enoxaparin 40 mg daily for VTE prophylaxis. (surgicalneurologyint.com)
Parameters1
  • Compared to the control group, some hematological parameters including MCV, platelets concentration, and APTT were modified in some but not all treatment groups. (scirp.org)
Enoxaparin3
Infusion4
  • The starting dose of CYANOKIT for adults is 5 g, administered by intravenous infusion over 15 minutes. (nih.gov)
  • The rate of infusion for the second 5 g dose may range from 15 minutes (for patients in extremis) to 2 hours based on patient condition. (nih.gov)
  • Therefore, the infusion dose should be reduced to 1 µg/kg/min in such patients (see DOSAGE AND ADMINISTRATION). (globalrph.com)
  • 5.Immediately following the bolus dose administration, initiate a continuous infusion of Eptifibatide. (wikidoc.org)
Based on the patient's1
  • Adjust the dose based on the patient's INR and the condition being treated. (druglib.com)
Adjust2
  • Adjust dose according to prescribing information if needed. (medscape.com)
  • Adjust the dose based on the desired clinical response. (rxlist.com)
Findings1
  • Although radiation has been thought to be, based on findings in high dose ranges, harmful no matter low the dose is, recent investigation revealed that living organisms possess the ability to respond to low-dose radiation in very sophisticated ways. (go.jp)
Last dose1
  • For participants in the dose-finding phase, a minimum washout period of at least 5 half-lives between the last dose of tyrosine kinase inhibitor (TKI) therapy and the first dose of study treatment is required. (dana-farber.org)
Single-dose2
  • Each single-dose, prefilled syringe of ARIXTRA, affixed with an automatic needle protection system, contains 2.5 mg of fondaparinux sodium in 0.5 mL, 5.0 mg of fondaparinux sodium in 0.4 mL, 7.5 mg of fondaparinux sodium in 0.6 mL, or 10.0 mg of fondaparinux sodium in 0.8 mL of an isotonic solution of sodium chloride and water for injection. (rxlist.com)
  • We previously developed a virus-like replicon particle (VRP) vaccine that provides complete protection against homologous and heterologous lethal CCHFV challenge in mice after a single dose. (cdc.gov)
Syringe1
  • 4.Withdraw the bolus dose(s) of Eptifibatide from the 10-mL vial into a syringe. (wikidoc.org)
High4
  • The concept was extended and applied to ionizing radiation, high doses of which are harmful. (go.jp)
  • A priming X-ray exposure to 0.05-0.10 Gy or 0.3-0.5 Gy imparts radioresistance (decrease in bone marrow death rate after high-dose X-rays) in mice 2-2.5 months or 9-17 days postexposure, respectively. (go.jp)
  • Dosing can be reduced to 110 mg twice a day in patients at high risk for bleeding or with mild renal impairment. (surgicalneurologyint.com)
  • In clinical signs, compound-colored stool was observed in all animals of treatment group (low: day 14 or 15, middle: day 8, high: day 8) and continuously observed up to the end of administration or day 1 of recovery period (high dose group). (eaht.org)
Guideline1
  • 6 The atherosclerotic cardiovascular disease risk estimator is available online and in mobile app format at http://my.americanheart.org/cvrisk calculator and at http://www.cardiosource.org/en/Science-And-Quality/Practice-Guidelines-and-Quality-Standards/2013-Prevention-Guideline-Tools.aspx . (aafp.org)
Days1
  • Females of childbearing potential must agree to abstain from sexual activity with nonsterilized male partners, or if sexually active with a nonsterilized male partner must agree to use highly effective methods of contraception from screening, throughout the study and agree to continue using such precautions for 100 days after the final dose of study intervention. (uclahealth.org)
Vial1
  • One 5 g vial is a complete starting dose. (nih.gov)
Study7
  • Note: patients in the dose-finding portion of the study may have received other anti-neoplastic therapy after progression on alectinib. (dana-farber.org)
  • ECOG PS ≤ 1 is required for participants in the dose-finding portion of the study. (dana-farber.org)
  • The purpose of this study is to compare any good and bad effects the study drug atezolizumab has on the cancer when combined with the standard chemotherapy drugs gemcitabine and cisplatin (or GC) in two different dosing schedules: chemotherapy (GC) before atezolizumab vs. GC after atezolizumab. (bcan.org)
  • Females of childbearing potential must be nonpregnant and nonlactating, or post-menopausal, and have a negative serum human chorionic gonadotropin (hCG) pregnancy test result at screening and a negative urine or serum pregnancy test prior to the first dose of study intervention. (uclahealth.org)
  • No testing guidelines were applicable for the pilot phase, as this part of the study was intended for dose level selection purposes only. (europa.eu)
  • Patients and Methods: The study comprised of 50 women of reproductive age group, divided into two equal and matched groups of 25 each, namely, a group of users of progestin-only injectable hormonal contraceptive Norethisterone oenanthate [NET EN] 200 μg used as a 2-monthly injection and a control group not using any hormonal contraception. (aku.edu)
  • Based on the results of the dose-range finding study (28-day repeated toxicity), GST was orally administered to rats at doses of 0, 500, 1000, and 2000 mg/kg B.W/day for 90-day and reversibility of effects of 2000 mg/kg bw/day was assessed after 4 weeks. (eaht.org)
Test1
  • There is no clinically available test (such as INR, aPTT, or anti-factor Xa level) to monitor dabigatran's efficacy. (jwatch.org)
Mice1
  • But mice pretreated at this priming dose did not show a marked recovery of peripheral blood cell counts after challenging irradiation with mid- or sublethal X-ray doses (a significant, albeit slight, increase in the blood cell counts in the preirradiated group was observed after a lower challenging exposure to 5.0 Gy). (go.jp)
Hours1
  • Formulations (w/w) were prepared daily within 6 hours prior to dosing and were homogenized to a visually acceptable level. (europa.eu)
Patients3
  • A dose reduction to 110 mg twice daily should be considered for patients with decreased renal function, elderly patients, and those with a history of gastrointestinal bleeding. (biomedcentral.com)
  • Although the number of events was limited, it should be noted that 3 patients in the very low-dose group had thromboembolic events. (biomedcentral.com)
  • Assess the safety and toxicity of atezolizumab in combination with immunogenic chemotherapy (gemcitabine plus oxaliplatin) with rituximab (R-GEMOX-ATEZO) in patients with relapsed or refractory (rel/ref) transformed diffuse large B-cell lymphoma (DLBCL), including determination of the maximum tolerated dose (MTD) and the recommended phase II dose (RP2D) of R-GEMOX-ATEZO. (ucsd.edu)
Daily1
  • Alternatively, a 2mg dose daily can be used with a two-week initial INR check. (gponline.com)
Safe1
  • PTT testing can help make sure the dose is safe and effective. (medlineplus.gov)